Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials.

Gilmore JL, Xiao HY, Dhar TGM, Yang MG, Xiao Z, Xie J, Lehman-McKeeman LD, Gong L, Sun H, Lecureux L, Chen C, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Borowski V, Warrack BM, Li Y, Shi H, Levesque PC, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Mathur A, Rampulla R, Gupta A, Pragalathan B, Shen DR, Cvijic ME, Salter-Cid LM, Carter PH, Dyckman AJ.

J Med Chem. 2019 Mar 14;62(5):2265-2285. doi: 10.1021/acs.jmedchem.8b01695. Epub 2019 Mar 6.

PMID:
30785748
2.

Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model.

Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, Li H, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lehman-McKeeman LD, Cherrington NJ.

Obesity (Silver Spring). 2017 Jun;25(6):1069-1076. doi: 10.1002/oby.21855. Epub 2017 Apr 28.

3.

Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P1 Receptor Modulator.

Yang MG, Xiao Z, Dhar TG, Xiao HY, Gilmore JL, Marcoux D, Xie JH, McIntyre KW, Taylor TL, Borowski V, Heimrich E, Li YW, Feng J, Fernandes A, Yang Z, Balimane P, Marino AM, Cornelius G, Warrack BM, Mathur A, Wu DR, Li P, Gupta A, Pragalathan B, Shen DR, Cvijic ME, Lehman-McKeeman LD, Salter-Cid L, Barrish JC, Carter PH, Dyckman AJ.

J Med Chem. 2016 Dec 22;59(24):11138-11147. doi: 10.1021/acs.jmedchem.6b01433. Epub 2016 Dec 7.

PMID:
28002964
4.

Identification of potent tricyclic prodrug S1P1 receptor modulators.

Marcoux D, Xiao HY, Murali Dhar TG, Xie J, Lehman-McKeeman LD, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Shi H, Levesque PC, Sun H, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Gupta A, Pragalathan B, Rampulla R, Mathur A, Shen DR, Cvijic ME, Salter-Cid L, Lombardo LJ, Carter PH, Dyckman AJ.

Medchemcomm. 2016 Nov 25;8(4):725-729. doi: 10.1039/c6md00539j. eCollection 2017 Apr 1.

5.

Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.

Dhar TG, Xiao HY, Xie J, Lehman-McKeeman LD, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Warrack B, Shi H, Levesque PC, Zhu JL, Hennan J, Balimane P, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Mathur A, Shen DR, Cvijic ME, Salter-Cid L, Barrish JC, Carter PH, Dyckman AJ.

ACS Med Chem Lett. 2016 Jan 19;7(3):283-8. doi: 10.1021/acsmedchemlett.5b00448. eCollection 2016 Mar 10.

6.

Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ.

Amino Acids. 2015 Mar;47(3):603-15. doi: 10.1007/s00726-014-1894-9. Epub 2014 Dec 23.

7.

Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ.

Dig Dis Sci. 2014 Feb;59(2):365-74. doi: 10.1007/s10620-013-2873-9. Epub 2013 Sep 19.

8.

Organic anion-transporting polypeptide 1a4 (Oatp1a4) is important for secondary bile acid metabolism.

Zhang Y, Csanaky IL, Selwyn FP, Lehman-McKeeman LD, Klaassen CD.

Biochem Pharmacol. 2013 Aug 1;86(3):437-45. doi: 10.1016/j.bcp.2013.05.020. Epub 2013 Jun 6.

9.

Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ.

Toxicol Appl Pharmacol. 2013 Apr 15;268(2):132-40. doi: 10.1016/j.taap.2013.01.022. Epub 2013 Feb 4.

10.

Establishment of a molecular embryonic stem cell developmental toxicity assay.

Panzica-Kelly JM, Brannen KC, Ma Y, Zhang CX, Flint OP, Lehman-McKeeman LD, Augustine-Rauch KA.

Toxicol Sci. 2013 Feb;131(2):447-57. doi: 10.1093/toxsci/kfs293. Epub 2012 Oct 5.

PMID:
23042729
11.

Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice.

Zhang Y, Limaye PB, Lehman-McKeeman LD, Klaassen CD.

PLoS One. 2012;7(4):e34522. doi: 10.1371/journal.pone.0034522. Epub 2012 Apr 4.

12.

Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury.

Zhang Y, Csanaky IL, Cheng X, Lehman-McKeeman LD, Klaassen CD.

Toxicol Sci. 2012 Jun;127(2):451-62. doi: 10.1093/toxsci/kfs123. Epub 2012 Mar 29.

13.

The Toxicology Education Summit: building the future of toxicology through education.

Barchowsky A, Buckley LA, Carlson GP, Fitsanakis VA, Ford SM, Genter MB, Germolec DR, Leavens TL, Lehman-McKeeman LD, Safe SH, Sulentic CE, Eidemiller BJ.

Toxicol Sci. 2012 Jun;127(2):331-8. doi: 10.1093/toxsci/kfs111. Epub 2012 Mar 29.

14.

Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability.

Zhang Y, Csanaky IL, Lehman-McKeeman LD, Klaassen CD.

Toxicol Sci. 2011 Dec;124(2):251-60. doi: 10.1093/toxsci/kfr236. Epub 2011 Sep 13.

15.

Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles.

Gong L, Aranibar N, Han YH, Zhang Y, Lecureux L, Bhaskaran V, Khandelwal P, Klaassen CD, Lehman-McKeeman LD.

Toxicol Sci. 2011 Aug;122(2):587-97. doi: 10.1093/toxsci/kfr114. Epub 2011 May 10.

PMID:
21561886
16.

Mapping progress in toxicology research by the content of the best papers published in Society of Toxicology Journals: a synopsis of the best paper awardees (1974-2011).

Lehman-McKeeman LD.

Toxicol Sci. 2011 Mar;120 Suppl 1:S1-7. doi: 10.1093/toxsci/kfq369. No abstract available.

PMID:
21342918
17.

Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example.

Liguori MJ, Ditewig AC, Maddox JF, Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Waring JF, Ganey PE, Roth RA, Blomme EA.

Int J Mol Sci. 2010 Nov 18;11(11):4697-714. doi: 10.3390/ijms11114697.

18.

Gamma-glutamyl transpeptidase null mice fail to develop tolerance to coumarin-induced Clara cell toxicity.

Vassallo JD, Kaetzel RS, Born SL, Lewis CL, Lehman-McKeeman LD, Reed DJ.

Food Chem Toxicol. 2010 Jun;48(6):1612-8. doi: 10.1016/j.fct.2010.03.034. Epub 2010 Mar 27.

PMID:
20347914
19.

Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin.

Vassallo JD, Janovitz EB, Wescott DM, Chadwick C, Lowe-Krentz LJ, Lehman-McKeeman LD.

Toxicol Sci. 2009 Oct;111(2):402-12. doi: 10.1093/toxsci/kfp166. Epub 2009 Jul 23.

PMID:
19628585
20.

Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR- rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidism.

Lecureux L, Dieter MZ, Nelson DM, Watson L, Wong H, Gemzik B, Klaassen CD, Lehman-McKeeman LD.

Toxicol Sci. 2009 Apr;108(2):482-91. doi: 10.1093/toxsci/kfp026. Epub 2009 Feb 11.

PMID:
19211616
21.

Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species.

Ren H, Vallanat B, Nelson DM, Yeung LWY, Guruge KS, Lam PKS, Lehman-McKeeman LD, Corton JC.

Reprod Toxicol. 2009 Jun;27(3-4):266-277. doi: 10.1016/j.reprotox.2008.12.011. Epub 2009 Jan 3.

PMID:
19162173
22.

Forum Series: the "Vision" for Toxicity Testing in the 21st Century: promises and conundrums.

Holsapple MP, Afshari CA, Lehman-McKeeman LD.

Toxicol Sci. 2009 Feb;107(2):307-8. doi: 10.1093/toxsci/kfn258. Epub 2008 Dec 9. No abstract available.

PMID:
19066395
23.

Beam me up Scotty: incorporating transporters in physiologically based pharmacokinetic-pharmacodynamic modeling.

Lehman-McKeeman LD.

Toxicol Sci. 2008 Jul;104(1):1-3. doi: 10.1093/toxsci/kfn075. Epub 2008 Apr 25. No abstract available.

PMID:
18441344
24.

p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine.

Deng X, Lu J, Lehman-McKeeman LD, Malle E, Crandall DL, Ganey PE, Roth RA.

J Pharmacol Exp Ther. 2008 Jul;326(1):144-52. doi: 10.1124/jpet.108.137497. Epub 2008 Apr 4.

25.

A retrospective analysis of toxicogenomics in the safety assessment of drug candidates.

Foster WR, Chen SJ, He A, Truong A, Bhaskaran V, Nelson DM, Dambach DM, Lehman-McKeeman LD, Car BD.

Toxicol Pathol. 2007 Aug;35(5):621-35. Review.

PMID:
17654404
26.

Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2.

Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ.

Drug Metab Dispos. 2007 Jun;35(6):995-1000. Epub 2007 Mar 12.

PMID:
17353348
27.

p53-independent induction of rat hepatic Mdm2 following administration of phenobarbital and pregnenolone 16alpha-carbonitrile.

Nelson DM, Bhaskaran V, Foster WR, Lehman-McKeeman LD.

Toxicol Sci. 2006 Dec;94(2):272-80. Epub 2006 Sep 25.

PMID:
17000718
28.

Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine.

Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Maddox JF, Ganey PE, Roth RA.

Toxicol Sci. 2006 Apr;90(2):569-85. Epub 2006 Jan 16.

PMID:
16415329
29.

Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.

Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Deng X, Maddox JF, Ganey PE, Roth RA.

J Pharmacol Exp Ther. 2006 May;317(2):635-43. Epub 2006 Jan 9.

PMID:
16401727
30.

Forum series: research strategies for safety evaluation of nanomaterials.

Holsapple MP, Lehman-McKeeman LD.

Toxicol Sci. 2005 Oct;87(2):315. No abstract available.

PMID:
16144823
31.

Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats.

Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, Shen HS, Gerson RJ, Car BD, Zhao B, Gemzik B.

Toxicol Sci. 2005 Apr;84(2):232-42. Epub 2005 Jan 26.

PMID:
15673846
32.

Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity.

Vassallo JD, Hicks SM, Daston GP, Lehman-McKeeman LD.

Toxicol Sci. 2004 Aug;80(2):249-57. Epub 2004 May 12.

PMID:
15141102
33.

A framework for human relevance analysis of information on carcinogenic modes of action.

Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE.

Crit Rev Toxicol. 2003;33(6):591-653. Review.

PMID:
14727733
34.

Liquid chromatographic determination of the glutathione conjugate and ring-opened metabolites formed from coumarin epoxidation.

Vassallo JD, Morrall SW, Fliter KL, Curry SM, Daston GP, Lehman-McKeeman LD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5;794(2):257-71.

PMID:
12954377
35.

Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis.

Hicks SM, Vassallo JD, Dieter MZ, Lewis CL, Whiteley LO, Fix AS, Lehman-McKeeman LD.

Toxicology. 2003 May 3;187(2-3):217-28.

PMID:
12699910
36.

Incorporating mechanistic data into risk assessment.

Lehman-McKeeman LD.

Toxicology. 2002 Dec 27;181-182:271-4.

PMID:
12505324
37.

Diethanolamine induces hepatic choline deficiency in mice.

Lehman-McKeeman LD, Gamsky EA, Hicks SM, Vassallo JD, Mar MH, Zeisel SH.

Toxicol Sci. 2002 May;67(1):38-45.

PMID:
11961214
38.

In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity.

Born SL, Caudill D, Smith BJ, Lehman-McKeeman LD.

Toxicol Sci. 2000 Nov;58(1):23-31.

PMID:
11053537
40.

o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin.

Born SL, Hu JK, Lehman-McKeeman LD.

Drug Metab Dispos. 2000 Feb;28(2):218-23.

PMID:
10640521
41.

Effects of musk xylene and musk ketone on rat hepatic cytochrome P450 enzymes.

Lehman-McKeeman LD, Caudill D, Vassallo JD, Pearce RE, Madan A, Parkinson A.

Toxicol Lett. 1999 Dec 20;111(1-2):105-15.

PMID:
10630706
42.

Development of tolerance to Clara cell necrosis with repeat administration of coumarin.

Born SL, Fix AS, Caudill D, Lehman-McKeeman LD.

Toxicol Sci. 1999 Oct;51(2):300-9.

PMID:
10543032
43.

Diethanolamine inhibits choline uptake and phosphatidylcholine synthesis in Chinese hamster ovary cells.

Lehman-McKeeman LD, Gamsky EA.

Biochem Biophys Res Commun. 1999 Sep 7;262(3):600-4.

PMID:
10471370
44.

alpha 2-Urinary globulin-associated nephropathy as a mechanism of renal tubule cell carcinogenesis in male rats.

Swenberg JA, Lehman-McKeeman LD.

IARC Sci Publ. 1999;(147):95-118. Review. No abstract available.

PMID:
10457913
45.

The structures of alpha 2u-globulin and its complex with a hyaline droplet inducer.

Chaudhuri BN, Kleywegt GJ, Björkman J, Lehman-McKeeman LD, Oliver JD, Jones TA.

Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):753-62.

PMID:
10089305
46.

Selective Clara cell injury in mouse lung following acute administration of coumarin.

Born SL, Fix AS, Caudill D, Lehman-McKeeman LD.

Toxicol Appl Pharmacol. 1998 Jul;151(1):45-56.

PMID:
9705886
47.

2-sec-butyl-4,5-dihydrothiazole is a ligand for mouse urinary protein and rat alpha 2u-globulin: physiological and toxicological relevance.

Lehman-McKeeman LD, Caudill D, Rodriguez PA, Eddy C.

Toxicol Appl Pharmacol. 1998 Mar;149(1):32-40.

PMID:
9512724
48.

Characterization of the effects of musk ketone on mouse hepatic cytochrome P450 enzymes.

Stuard SB, Caudill D, Lehman-McKeeman LD.

Fundam Appl Toxicol. 1997 Dec;40(2):264-71.

PMID:
9441723
49.
50.

Synthesis and reactivity of coumarin 3,4-epoxide.

Born SL, Rodriguez PA, Eddy CL, Lehman-McKeeman LD.

Drug Metab Dispos. 1997 Nov;25(11):1318-24.

PMID:
9351910

Supplemental Content

Loading ...
Support Center